Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYLYNK-001 first-line advanced BRCA non-mutated epithelial ovarian cancer study
2018-001973-25Phase 3Active
- Sponsor
- Merck & Co.
- Start
- Oct 2018
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of pembrolizumab and olaparib in epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC) (2 arms), sponsored by Merck & Co. Primary endpoint: Progression-free survival. Started Oct 2018; status: active.
02
Drugs
pembrolizumabolaparib
03
Conditions
epithelial ovarian cancer (EOC)primary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on 2018-001973-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001973-25.